Authorizes Booster sheep of Pfizer-BioNTech COVID-19 Vaccine for specific Populations


Today, the U.S. Food and Drug management amended the emergency usage authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to permit for use of a single booster dose, to it is in administered at the very least six months after completion of the primary series in:

individuals 65 year of age and older;individuals 18 with 64 years of period at high danger of serious COVID-19; and individuals 18 with 64 year of period whose frequent institutional or work-related exposure come SARS-CoV-2 place them at high danger of serious complications of COVID-19 including severe COVID-19.

You are watching: Is pfizer covid vaccine fda approved

Today’s authorization applies only come the Pfizer-BioNTech COVID-19 Vaccine. 

“Today’s action demonstrates the science and the currently available data proceed to overview the’s decision-making because that COVID-19 vaccines during this pandemic. ~ considering the totality that the obtainable scientific evidence and also the deliberations of our advisory committee that independent, exterior experts, the amended the EUA for the Pfizer-BioNTech COVID-19 Vaccine to permit for a booster dose in specific populations such as health care workers, teachers and day care staff, grocery workers and those in homeless house or prisons, amongst others,” stated Acting Commissioner Janet Woodcock, M.D. “This pandemic is dynamic and evolving, with brand-new data around vaccine safety and effectiveness becoming accessible every day. Together we learn much more about the safety and also effectiveness the COVID-19 vaccines, including the use of a booster dose, we will proceed to evaluate the rapidly an altering science and also keep the general public informed.”

The process for Assessing the easily accessible Data

Comirnaty (COVID-19 Vaccine, mRNA), was authorized by the ~ above Aug. 23, because that the avoidance of COVID-19 resulted in by SARS-CoV-2 in individuals 16 years of age and older. ~ above Aug. 25, 2021, the obtained a complement from Pfizer Inc. To their biologics patent application for Comirnaty search approval the a single booster sheep to be administered about six months after completion of the main vaccination series for individuals 16 years of age and also older.

As part of the’s commitment to transparency, the agency convened a public conference of the Vaccines and also Related organic Products Advisory Committee (VRBPAC) top top Sept. 17 come solicit input indigenous independent scientific and public health specialists on the data it is registered in the application. Throughout the meeting, the vaccine manufacturer gift information and data in support of the application. The additionally presented its evaluation of clinical attempt data it is registered by the vaccine manufacturer. Additionally, the public was also given an chance to carry out comment; and also invited international and also U.S. Agencies and external groups, including representatives native the Israeli set of Health, the college of Bristol, U.K. And also the Centers for disease Control and Prevention, to existing recent data top top the use of vaccine boosters, epidemiology of COVID-19, and also real-world evidence on vaccine effectiveness.

The thought about the data the the vaccine manufacturer submitted, information presented in ~ the VRBPAC meeting, and the committee’s discussion, and also has determined that based on the totality the the accessible scientific evidence, a booster dose of Pfizer-BioNTech COVID-19 Vaccine might be efficient in avoiding COVID-19 and also that the known and also potential services of a booster dose outweigh the known and also potential dangers in the populaces that the is authorizing because that use. The booster dose is authorized for management to these individuals at the very least six months following completion of their primary series and may be given at any suggest after that time.

It’s necessary to keep in mind that the Pfizer-BioNTech COVID-19 Vaccine is the exact same formulation as the Comirnaty and also the vaccines may be offered interchangeably. 

“We’re grateful for the advice of the doctors, scientists, and also leading vaccine experts on our advisory committee and the important duty they have played in ensuring transparent discussions about COVID-19 vaccines. We appreciate the robust discussion, including the vote concerning individuals over 65 year of age and individuals at high hazard for significant disease, and the committee’s views about the use of a booster dose because that those through institutional or occupational exposure come SARS-CoV-2,” said Peter Marks, M.D., Ph.D., director of’s facility for Biologics Evaluation and Research. “The thought about the committee’s input and conducted its very own thorough evaluation of the submitted data to with today’s decision. We will proceed to analysis data submitted to the pertaining to the use of booster doses of COVID-19 vaccines and we will certainly make further decisions as ideal based top top the data.” 

Data supporting Authorization because that Emergency Use

To support the authorization for emergency use of a solitary booster dose, the analyzed safety and immune an answer data native a subset that participants indigenous the initial clinical psychological of the Pfizer-BioNTech COVID-19 Vaccine. In addition, factor to consider was provided to real-world data on the vaccine’s efficacy over a sustained period of time detailed by both U.S. And also international sources, including the CDC, the UK and also Israel. The immune responses of roughly 200 participants 18 through 55 years of period who got a solitary booster dose about six month after their 2nd dose were assessed. The antibody response versus SARS-CoV-2 virus one month ~ a booster dose of the vaccine compared to the solution one month after the two-dose primary collection in the same individuals demonstrated a booster response. 

Additional analysis conducted by the manufacturer, as asked for by the, contrasted the rates of COVID-19 accrued throughout the existing Delta different surge amongst original clinical trial participants who completed the primary two-dose vaccination series early in the clinical trial to those that completed a two-dose collection later in the study. The evaluation submitted through the agency showed that throughout the study duration of July and also August 2021, the incidence of COVID-19 was higher among the participants who completed their main vaccine collection earlier, compared to participants who completed it later. The established that the rate of breakthrough COVID-19 reported throughout this time period translates come a modest decrease in the efficacy the the vaccine among those vaccinated earlier.

Safety to be evaluated in 306 attendees 18 through 55 years of age and 12 entrants 65 years of age and older who were followed for an mean of over two months. The most generally reported side effects by the clinical trial participants who obtained the booster dose of the vaccine were pain, redness and swelling in ~ the injection site, as well as fatigue, headache, muscle or joint pain and chills. That note, swollen lymph nodes in the underarm to be observed much more frequently complying with the booster dose than after the main two-dose series.

See more: Watch: This "Prequel" To Back To The Future Prequel Is Too Good To Be True

Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA for people 16 years of age and older. The authorization was expanded on may 10, 2021 to encompass those 12 with 15 year of age, and also again on Aug. 12, 2021 to incorporate the use of a third dose of a three-dose primary collection in details immunocompromised people 12 years of age and older. EUAs have the right to be supplied by the throughout public wellness emergencies come provide access to medical products that may be reliable in preventing, diagnosing, or treating a disease, noted that the determines the the known and also potential services of a product, when used to prevent, diagnose, or law the disease, outweigh the known and potential threats of the product.

The amendment come the EUA to encompass a solitary booster dose to be granted to Pfizer Inc.